CJC 1295 DAC

CJC 1295 DAC is a long-acting growth hormone-releasing hormone (GHRH) analog designed to increase and sustain growth hormone (GH) and IGF-1 levels in the body. The “DAC” (Drug Affinity Complex) component significantly extends the half-life of the peptide, allowing for less frequent dosing—often as little as once or twice per week.

Originally developed for clinical applications related to growth hormone deficiency, CJC-1295 DAC is now widely used in the research and wellness communities for its potential benefits in muscle growth, fat loss, recovery, and anti-aging. It stimulates the pituitary gland to naturally release GH in pulses, aligning with the body’s biological rhythms.

Key Features:

• Extended half-life (~8 days) due to DAC binding
• Promotes sustained release of growth hormone
• May improve lean muscle mass, reduce fat, and support recovery
• Commonly used in bodybuilding and longevity research

CJC-1295 DAC differs from CJC-1295 without DAC (also known as Mod GRF 1-29) by offering longer duration and more stable blood levels, making it ideal for those seeking less frequent injection

CJC 1295  DAC is a long acting Growth Hormone Releasing Hormone, which causes the anterior pituitary  to release more growth hormone. GHRH is released in pulses in the body, which alternate with corresponding pulses of somatostatin (growth-hormone inhibiting-hormone). Clinical Research was first conducted for CJC 1295 during the mid-2000s. The objective of the peptide was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous HGH are presumed to increase lipolysis (fat loss). The clinical research was ultimately successful for most research subjects. Ghrelin, released from the gut, which circulates and acts as a hunger hormone, has synergistic activity in the body with GHRH and also suppresses somatostatin to make way for the GHRH pulse. Studies shows that combining a GHRP-6 with CJC 1295 DAC, significantly increase the release of GH and IGF-1 production without an increase in prolactin. An example of a GHRP (GH Releasing Peptide) is Hexarelin or GHRP-2. CJC 1295  DAC is a exceptionally designed peptide and is known for being the finest of the hGH secretogues. The DAC (Drug Affinity Complex) portion increases the half-life by binding with serum albumin and protects the CJC 1295 DAC peptide from degradation. This was formed when a lysine link was bounded to DACs to a reactive chemical called maleimidoproprionic acid (MPA).

CJC 1295 DAC Dosage Per Day 

When discussing CJC 1295 DAC dosage per day, it’s important to understand that this version of the peptide is designed for weekly, not daily administration due to its long half-life. The “DAC” (Drug Affinity Complex) component allows the peptide to remain active in the body for up to 8–10 days, meaning daily dosing is unnecessary and not typically recommended.

Standard Dosage Guidelines:

• Typical Dose: 1–2 mg per week
• Administration Frequency: Once or twice per week
• Injection Method: Subcutaneous (under the skin)

Some users split the total weekly dosage into two injections (e.g., 1 mg on Monday, 1 mg on Thursday) to maintain more stable levels, but daily dosing is not common with DAC-bound CJC-1295. For daily protocols, CJC-1295 without DAC (Mod GRF 1-29) is more appropriate due to its short half-life.

Important Notes:

• Higher doses do not always lead to better results and may increase side effect risks.
• Best administered on an empty stomach, ideally before bed or post-workout for maximum growth hormone release.
• Should be stored and handled according to research guidelines.

CJC 1295 with DAC Dosage 

CJC-1295 with DAC is a long-acting peptide analog of growth hormone-releasing hormone (GHRH), designed to stimulate the body’s natural production of growth hormone (GH) and IGF-1 over an extended period. Thanks to the Drug Affinity Complex (DAC), this compound has a half-life of about 8 to 10 days, allowing for weekly rather than daily administration.

Recommended Dosage:

• Typical Dose: 1 mg to 2 mg once per week
• Injection Route: Subcutaneous (into the fat layer under the skin)
• Cycle Length: 8 to 12 weeks, depending on research goals

Some research protocols split the dose into two smaller injections (e.g., 1 mg twice a week) to help maintain stable plasma levels, but this is optional given the long half-life.

Why Weekly Dosing?

CJC-1295 with DAC stays active in the bloodstream for days, continuously stimulating GH release. Unlike short-acting peptides like CJC-1295 without DAC (Mod GRF 1-29), it does not require daily injections, making it more convenient and consistent in long-term studies.

Stacking:

CJC-1295 with DAC is often stacked with Ipamorelin in research for synergistic GH release while minimizing side effects like cortisol or prolactin spikes

CJC 1295 DAC vs. CJC 1295 without DAC

CJC-1295 + DAC and CJC-1295 (also known as Modified GRF 1-29) are both Growth Hormone Releasing Hormones (GHRH). Their action in the human body is identical but the difference between the two peptides are the span of the half-life. Modified GRF 1-29 and Sermorelin have a very short acting half-life of about 30 minutes, while CJC-1295 + DAC has a half-life that can last up to approximately 8 days. Many a scientist have reported that the short half-life of Sermorelin and Modified GRF 1-29 is considered to be much more natural as they produce a short pulse of Human Growth Hormone.

ConjuChem and The Development of CJC 1295 DAC

CJC 1295 DAC is a tetrasubstituted peptide analogue of Growth Hormone Releasing Hormones with D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27. A Canadian biotechnology company called ConjuChem had invented CJC 1295. Clinical Research on CJC-1295 first began during the mid-2000s. The goal of the peptide, acting to raise HGH like Ipamorelin, was to treat visceral fat deposits in obese AIDS patients because it is presumed that increased levels of exogenous hgH increase fat loss, or lipolysis. In one study, results showed that the measured GH release in rats over a two hour period showed that CJC 1295 released twice as much GH as CJC 1293  DAC. This result makes it preferable for immediate effectiveness as a result of the longer peak. With the use of a Growth Hormone Releasing Peptide (GHRP), such as Growth Hormone Releasing Hexapeptide (GHRP-6) in conjuction with CJC 1295   DAC, a study has shown that the GHRP’s create a Growth Hormone pulse which helps the CJC 1295 work effectively. Clinical research’s involving CJC 1295 have shown that it had been successful for most research subjects.

FAQs – CJC 1295 DAC

1. What is CJC-1295 DAC?
   CJC-1295 DAC is a synthetic peptide that stimulates the release of growth hormone (GH) by mimicking the body’s natural GHRH (Growth Hormone-Releasing Hormone). The addition of DAC (Drug Affinity Complex) extends its half-life, allowing for weekly injections instead of daily.
2. What does “with DAC” mean?
   “DAC” stands for Drug Affinity Complex, a modification that binds the peptide to albumin in the bloodstream. This prolongs its activity to around 8–10 days, making it far more stable and long-acting than CJC-1295 without DAC.
3. What is the typical dosage for CJC-1295 DAC?
   The standard research dosage is 1–2 mg per week, administered subcutaneously. Due to its long half-life, it does not require daily administration.
4. What are the potential benefits of CJC-1295 DAC?
   In research settings, it has been studied for benefits such as:
   • Increased growth hormone and IGF-1 levels
   • Improved muscle growth and fat loss
   • Enhanced recovery and sleep quality
   • Anti-aging and regenerative effects
5. How is CJC-1295 DAC different from CJC-1295 without DAC (Mod GRF 1-29)?
   CJC-1295 with DAC has a much longer half-life and is dosed weekly. In contrast, Mod GRF 1-29 (without DAC) has a short half-life (30 minutes) and must be administered multiple times per day for sustained GH release.
6. Can CJC-1295 DAC be stacked with other peptides?
   Yes. It is commonly stacked with Ipamorelin, another growth hormone secretagogue, for a synergistic effect that enhances GH release without increasing cortisol or prolactin.
7. Are there any side effects?
   Reported side effects in research settings may include water retention, tingling or numbness in extremities, fatigue, and mild injection site reactions. Effects are generally dose-dependent.
8. Is CJC-1295 DAC approved for human use?
   No. CJC-1295 DAC is for research purposes only and is not approved for medical or human use outside of controlled studies.
9. How should it be stored?
   Lyophilized (dry) CJC-1295 DAC should be stored in a cool, dry place. Once reconstituted with bacteriostatic water, it should be refrigerated and used within a specified timeframe based on research protocols.
10. How long does it take to see results in research settings?
    Some studies suggest noticeable effects (e.g., improved recovery, better sleep, increased lean mass) may begin to appear after 3–4 weeks, with more pronounced benefits over 8–12 weeks.